Business Combination, Percent of Cash Consideration Transferred

No definition available.

Name:	exas_BusinessCombinationPercentOfCashConsiderationTransferred
Namespace Prefix:	exas_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Percent of Equity Consideration Transferred

+ References

No definition available.

+ Details

Name:	exas_BusinessCombinationPercentOfEquityConsiderationTransferred
Namespace Prefix:	exas_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the amount of net sales of a licensed product considered as a milestone under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	exas_CollaborativeArrangementsSalesMilestoneAmount
Namespace Prefix:	exas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment to Acquire Intangible Assets, Shares

+ References

No definition available.

+ Details

Name:	exas_PaymentToAcquireIntangibleAssetsShares
Namespace Prefix:	exas_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents potential future payments still contingent upon achievement of milestones under a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	exas_PaymentsContingentOnMilestones
Namespace Prefix:	exas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Stock Issued to Acquire Intangible Assets, Value

+ References

No definition available.

+ Details

Name:	exas_StockIssuedToAcquireIntangibleAssetsValue
Namespace Prefix:	exas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=exas_TranslationalGenomicsResearchInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=exas_AshionAnalyticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exas_CollaborativeArrangementsSalesMilestoneAxis=exas_SalesMilestoneRangeOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exas_CollaborativeArrangementsSalesMilestoneAxis=exas_SalesMilestoneRangeTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=exas_ThriveEarlierDetectionCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=exas_JohnHopkinsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exas_CollaborativeArrangementsSalesMilestoneAxis=exas_SalesMilestoneRangeThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUBSEQUENT EVENTS (Details) $ in Thousands, € in Millions	Feb. 12, 2021 USD ($) shares	Feb. 12, 2021 EUR (€) shares	Jan. 11, 2021 USD ($) shares	Jan. 11, 2021 EUR (€) shares	Jan. 05, 2021 USD ($)	Jan. 05, 2021 EUR (€)	Nov. 08, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Subsequent Event [Line Items]
Business combination, consideration transferred							$ 2,470,000
Contingent consideration, liability								$ 2,477	$ 2,879
Subsequent Event
Subsequent Event [Line Items]
Stock issued to acquire intangible assets, value			$ 27,300
Subsequent Event \| Translational Genomics Research Institute \| Licensing Agreements
Subsequent Event [Line Items]
Purchases of intangible assets			$ 25,000
Payment to acquire exclusive license (in shares) \| shares			191,336	191,336
Subsequent Event \| Ashion Analytics \| Licensing Agreements
Subsequent Event [Line Items]
Net sales of a licensed product	$ 500,000
Cash investment	$ 72,000
Equity issued to acquire business (in shares) \| shares	125,444	125,444
Subsequent Event \| Sales Milestone Range One \| Translational Genomics Research Institute \| Licensing Agreements
Subsequent Event [Line Items]
Payment contingent upon achievement of milestone \| €				€ 10.0
Net sales of a licensed product			$ 100,000
Subsequent Event \| Sales Milestone Range One \| Ashion Analytics \| Licensing Agreements
Subsequent Event [Line Items]
Payment contingent upon achievement of milestone \| €		€ 20.0
Subsequent Event \| Sales Milestone Range Two \| Translational Genomics Research Institute \| Licensing Agreements
Subsequent Event [Line Items]
Payment contingent upon achievement of milestone \| €				€ 35.0
Net sales of a licensed product			$ 250,000
Subsequent Event \| Sales Milestone Range Two \| Ashion Analytics \| Licensing Agreements
Subsequent Event [Line Items]
Payment contingent upon achievement of milestone \| €		€ 30.0
Thrive \| Subsequent Event
Subsequent Event [Line Items]
Business combination, consideration transferred					$ 1,700,000
Business combination, percent of cash consideration transferred					35.00%
Business combination, percent of equity consideration transferred					65.00%
Contingent consideration, liability					$ 450,000
Thrive \| Subsequent Event \| Sales Milestone Range One \| John Hopkins License Agreement \| Licensing Agreements
Subsequent Event [Line Items]
Payment contingent upon achievement of milestone \| €						€ 10.0
Net sales of a licensed product					500,000
Thrive \| Subsequent Event \| Sales Milestone Range Two \| John Hopkins License Agreement \| Licensing Agreements
Subsequent Event [Line Items]
Payment contingent upon achievement of milestone \| €						15.0
Net sales of a licensed product					1,000,000
Thrive \| Subsequent Event \| Sales Milestone Range Three \| John Hopkins License Agreement \| Licensing Agreements
Subsequent Event [Line Items]
Payment contingent upon achievement of milestone \| €						€ 20.0
Net sales of a licensed product					$ 1,500,000